Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin

Ítems similars

• Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
  per: Ramakrishnan, V, et al.
  Publicat: (2009)
• MRK003, a Gamma Secretase Inhibitor exhibits promising in vitro pre-clinical activity in Multiple Myeloma and Non Hodgkin's Lymphoma
  per: Ramakrishnan, Vijay, et al.
  Publicat: (2011)
• TG101209, a novel JAK2 inhibitor, has significant in-vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells
  per: Ramakrishnan, Vijay, et al.
  Publicat: (2010)
• The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
  per: Tesori, Valentina, et al.
  Publicat: (2015)
• Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001
  per: Ramakrishnan, Vijay, et al.
  Publicat: (2014)